Organon stock holds steady as investors watch post-spin growth story

Organon stock is trading in the mid-teens as investors weigh the company’s latest revenue trends, margin profile and market cap in the context of its post-Merck spin-off growth ambitions.

Organon stock (ISIN US68622V1061) is trading in the mid-teens in USD as of September 3, 2026, leaving the women’s health and biosimilars specialist valued at around USD 2.7 billion according to market data compiled by Macrotrends.

Revenue scale and margin profile

Organon and Co. emerged from its spin-off as a mid-cap pharmaceutical company with annual revenue in the multi-billion USD range and a focus on women’s health therapies, established brands and biosimilars. In its most recently reported full fiscal year within the past two years, the company generated several billion USD of revenue, underlining that the current market capitalization of USD 2,698.0 million as listed for Organon on Macrotrends values the business at slightly below one times annual sales.

For investors, that revenue-to-market-capitalization ratio is an important benchmark. A company with a stable multi-billion USD top line and a market value of about USD 2.7 billion tends to trade at lower multiples than large-cap peers in the branded pharmaceuticals space, where price-to-sales ratios of 3.0 or above are common. That comparison helps frame Organon’s equity story as a value-oriented play in specialty pharma rather than a high-multiple growth stock.

Organon stock price level and market valuation

On the price side, Organon’s New York Stock Exchange listing under the ticker OGN shows a quotation in the area of USD 13.78 per share with a marginal daily move of 0.11 percent as of the latest closing snapshot, according to MarketBeat. That closing price places the stock comfortably above levels seen shortly after the spin-off, when Organon traded in the single digits, and it reflects a gain of more than 90 percent from those lows based on longer-term performance data referenced in the same overview.

In parallel, another data point from Macrotrends shows Organon’s market capitalization at USD 2.698 billion, paired with a price-to-earnings ratio of 2.94. A single-digit price-to-earnings multiple of roughly 2.9 sits far below the typical mid-teens or low-twenties range for diversified pharma companies, signaling that the market is still pricing in execution risk around the portfolio and potential pressure on legacy products.

Women’s health and established brands as key pillars

Organon’s portfolio centers on women’s health medicines, contraception, fertility treatments and therapies addressing conditions such as endometriosis. In addition, the company manages a significant stable of established brands in areas like cardiovascular and respiratory therapy, which continue to generate cash flow even as they face generic competition. Biosimilars form a third strategic pillar, offering lower-cost alternatives to biologic drugs while tapping into partnerships and in-licensed assets.

That mix of segments is designed to balance growth and stability. Women’s health products give Organon exposure to under-served therapeutic areas where demand may grow faster than the overall pharma market, while established brands and biosimilars support margin resilience and cash generation needed to service debt and fund dividends. For shareholders, the question is how quickly the growth engines can offset any decline in legacy products and whether new launches and geographic expansion can lift revenue and earnings beyond the levels implied by today’s low valuation multiples.

Stock performance perspective for investors

From a performance angle, Organon stock around USD 13.78, as indicated by MarketBeat data for the latest trading session, represents a recovery compared with the lows shortly after the spin-off, with the MarketBeat overview noting that the shares have risen by more than 90 percent from those trough levels. That quantified rebound shows the market’s willingness to re-rate the company as clarity around its stand-alone strategy improved and investors digested its balance-sheet profile.

At the same time, the comparatively modest market capitalization of approximately USD 2.7 billion highlighted in the Macrotrends capitalization table underscores that Organon remains a mid-cap name rather than a large-cap pharma heavyweight. For many retail investors, that positioning offers both opportunity and risk: the upside potential if execution on women’s health and biosimilars exceeds expectations, and the downside if competitive or regulatory pressures weigh more heavily than the market currently assumes.

Representative product focus

One representative product category for Organon lies in long-acting reversible contraception, where the company markets devices and hormonal treatments designed to offer reliable, multi-year protection. These products sit at the intersection of women’s health, reproductive autonomy and public-health policy, making them strategically important for the brand and for payers. Revenue from such contraception products contributes meaningfully to the women’s health segment and helps differentiate Organon’s portfolio from that of more generalist pharma groups.

Price snapshot and trading venue

Organon stock is listed on the New York Stock Exchange under the ticker OGN, with recent data from MarketBeat indicating a closing price of about USD 13.78 per share and a marginal 0.11 percent move in the latest trading session, as of early September 2026. That price level, combined with the USD 2.698 billion market capitalization figure from Macrotrends, frames the equity as a mid-cap specialty pharma investment that is still trading at relatively low valuation multiples compared with many global peers.

Organon stock at a glance

• Company: Organon and Co.
• ISIN: US68622V1061
• Ticker: OGN
• Trading venue: NYSE
• Price (as of September 3, 2026): 13.78 USD
• Market capitalization: 2,698.0 million USD (as of early September 2026)
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: Not part of a major blue-chip index such as the S&P 500 or DAX